more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

-0.22 (-0.77%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

Top 23% (53 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO

by Zacks Equity Research Published on December 21,2021

Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.

Glaxo (GSK) Gets FDA Nod for HIV Preventive Injectable Drug

by Zacks Equity Research Published on December 21,2021

Glaxo's (GSK) Apretude is the first and only long-acting injectable therapy approved for HIV prevention or PrEP.

pharmaceuticals

Moderna (MRNA) COVID-19 Booster Jab Effective Against Omicron

by Zacks Equity Research Published on December 21,2021

Data from a pseudovirus study demonstrated that the authorized booster dose of Moderna's (MRNA) COVID-19 vaccine significantly increases neutralizing antibody levels against the Omicron variant.

biotechs

Biotech ETFs That Outperformed Last Week

by Sweta Killa Published on December 20,2021

Biotech ETFs was the biggest gainer last week.

Pfizer (PFE) to Test 3-Dose COVID-19 Vaccine Regimen in Kids

by Zacks Equity Research Published on December 20,2021

Pfizer (PFE) and BioNTech (BNTX) to evaluate a third, 3 ug dose at least two months after the second dose of Comirnaty in children aged six months to five years for better protection against COVID-19.

pharmaceuticals

Tech-Stocks Under Pressure in the Pre-Markets

by Zacks Equity Research Published on December 17,2021

Tech-Stocks Under Pressure in the Pre-Markets

Markets Stay Red: Time for a Little Xmas Shopping?

by Mark Vickery Published on December 17,2021

It's shaping up like a down week in the markets overall, despite a nice push higher following the most recent Fed policy adjustment mid-week.

retail

Pfizer (PFE) COVID Pill Paxlovid Gets CHMP Support in Europe

by Zacks Equity Research Published on December 17,2021

The CHMP supports the use of Pfizer's (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.

pharmaceuticals

U.S. CDC Recommends mRNA COVID-19 Vaccines Over J&J's Jab

by Indrajit Bandyopadhyay Published on December 17,2021

The U.S. Centers for Disease Control and Prevention prefers the use of PFE, BNTX and MRNA's mRNA-based COVID-19 vaccines instead of J&J's adenovirus-based vaccine due to higher risks of side effects.

Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More

by Kinjel Shah Published on December 17,2021

Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.

pharmaceuticals

Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod

by Zacks Equity Research Published on December 16,2021

Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

J&J's (JNJ) COVID-19 Booster Jab Gets CHMP Recommendation

by Zacks Equity Research Published on December 16,2021

The CHMP recommends the use of the booster dose of J&J's (JNJ) COVID-19 vaccine in adults in Europe. The booster jab already enjoys authorization in the United States and from the WHO for use in adults.

pharmaceuticals

Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid Tumors

by Zacks Equity Research Published on December 16,2021

Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.